PTEN loss and p27 loss differ among morphologic patterns of prostate cancer, including cribriform

Hum Pathol. 2017 Jul:65:85-91. doi: 10.1016/j.humpath.2017.04.024. Epub 2017 May 10.

Abstract

The presence and extent of cribriform pattern of prostate cancer portend recurrence and cancer death. The relative expressions within this morphology of the prognostically adverse loss of PTEN, and the downstream inactivation of cell cycle inhibitor p27/Kip1 had been uncertain. In this study, we examined 52 cases of cribriform cancer by immunohistochemistry for PTEN, p27, and CD44 variant (v)7/8, and a subset of 17 cases by chromogenic in situ hybridization (ISH) using probes for PTEN or CDKN1B (gene for p27). The fractions of epithelial pixels positive by immunohistochemistry and ISH were digitally assessed for benign acini, high-grade prostatic intraepithelial neoplasia, and 8 morphologic patterns of cancer. Immunostaining results demonstrated that (1) PTEN loss was significant for fused small acini, cribriform-central cells, small cribriform acini, and Gleason grade 5 cells in comparison with other acini; (2) p27 loss was significant only for cribriform-peripheral cells and borderline significant for fused small acini in comparison with benign acini; and (3) CD44v7/8 showed expression loss in cribriform-peripheral cells; other comparisons were not significant. ISH showed that cribriform cancer had significant PTEN loss normalized to benign acini (P<.02), whereas Gleason 3 cancer or fused small acini did not. With CDKN1B, the degree of signal loss among various cancer morphologies was insignificant. In conclusion, molecular disparities emerged between the fused small acini and cribriform patterns of Gleason 4 cancer. PTEN or p27 loss as prognostic factors demands distinct assessment in the varieties of Gleason 4 cancer, and in the biphenotypic peripheral versus central populations in cribriform structures.

Keywords: CD44; CDKN1B; Gleason grading; PTEN; Prostate cancer; p27.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / analysis*
  • Biomarkers, Tumor / genetics
  • Biopsy
  • Cyclin-Dependent Kinase Inhibitor p27 / analysis*
  • Cyclin-Dependent Kinase Inhibitor p27 / genetics
  • Down-Regulation
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization
  • Male
  • Middle Aged
  • Neoplasm Grading
  • PTEN Phosphohydrolase / analysis*
  • PTEN Phosphohydrolase / genetics
  • Predictive Value of Tests
  • Prostatectomy
  • Prostatic Neoplasms / enzymology*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / surgery

Substances

  • Biomarkers, Tumor
  • CDKN1B protein, human
  • Cyclin-Dependent Kinase Inhibitor p27
  • PTEN Phosphohydrolase
  • PTEN protein, human